Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

G. Taylor-Stokes



Author of

  • +

    OA 11 - Reducing Burden: Patient-Centered Care (ID 682)

    • Event: WCLC 2017
    • Type: Oral
    • Track: Nursing/Palliative Care/Ethics
    • Presentations: 1
    • +

      OA 11.01 - Impact of Tobacco Smoking on the Humanistic and Financial Burden of Advanced Non-Small Cell Lung Cancer (A-NSCLC) (ID 8662)

      11:00 - 11:10  |  Author(s): G. Taylor-Stokes

      • Abstract
      • Presentation
      • Slides

      Background:
      Tobacco smoking has a negative impact on the prognosis of A-NSCLC. It is less well known how smoking impacts the burden of disease. As such, an analysis was conducted to evaluate the impact of a current tobacco smoking habit and/or history of smoking on the burden of A-NSCLC.

      Method:
      Data were collected between May 2015 and June 2016 from adult patients with Stage IIIB or IV NSCLC via medical chart reviews and patient self-completion forms as part of a multicentre, cross-sectional study conducted in France, Germany and Italy. Health status was measured using the EQ-5D-3L (including the visual analogue scale, EQ-VAS), quality of life (QoL) using the EORTC QLQ-C30 and work/activity impairment using the WPAI:GH questionnaire. Costs of NSCLC-related productivity losses and out-of-pocket expenses were also collected. Outcomes were stratified by smoking status (current/former smoker vs never smoked); no adjustments were made for possible confounding factors. Statistical significance was assessed using Mann–Whitney U tests.

      Result:
      1030 patients were recruited: mean patient age, 64.5 years; male, 65.9%; Stage IV NSCLC, 88.4%; non-squamous histology, 70.3%; receiving first-line therapy, 70.5%. Patients were largely receiving chemotherapy, regardless of line of therapy. In total, 1010 patients had smoking status recorded; 787 (77.9%) were current/former smokers and 223 (22.1%) had never smoked. Significant differences were observed between current/former smokers and patients who had never smoked for health status, QoL, work- and activity-related impairments, and NSCLC-related costs (TABLE). Figure 1



      Conclusion:
      A significant deterioration in health status and QoL, along with greater work- and activity-related impairments, was observed in current/former smokers with A-NSCLC. Moreover, costs of NSCLC-related productivity losses and out-of-pocket expenses were also higher versus those who had never smoked. These findings suggest an association between tobacco smoking and the humanistic and financial burden incurred by patients with A-NSCLC.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.01 - Advanced NSCLC (ID 618)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P2.01-012 - Impact of Brain Metastases on the Humanistic Burden Incurred by Patients with Advanced Non-small Cell Lung Cancer (A-nsclc) (ID 8179)

      09:00 - 09:00  |  Author(s): G. Taylor-Stokes

      • Abstract
      • Slides

      Background:
      It is well documented that brain metastases negatively impact the prognosis for patients with A-NSCLC. However, it is less well known how secondary brain tumours impact health status, quality of life (QoL) and productivity in these patients. As such, an analysis of data from A-NSCLC patients was conducted to evaluate whether the metastatic site (brain vs non-brain) impacts the burden of disease.

      Method:
      Data were collected between May 2015 and June 2016 from adult patients with Stage IIIB or IV NSCLC via medical chart reviews and patient self-completion forms as part of a multicentre, cross-sectional study conducted in France, Germany and Italy. Health status was measured using the EQ-5D-3L (including the visual analogue scale, EQ-VAS), QoL using the EORTC QLQ-C30 and work/activity impairment using the WPAI:GH questionnaire. Outcomes were stratified by metastatic site (brain vs non-brain); no adjustments were made for possible confounding factors. Statistical significance was assessed using Mann–Whitney U tests.

      Result:
      1030 patients were recruited: mean patient age, 64.5 years; male, 65.9%; current/former smokers, 77.9%. Most patients had Stage IV NSCLC (88.4%), non-squamous histology (70.3%) and/or were receiving first-line therapy (70.5%). Patients were largely receiving chemotherapy, regardless of line of therapy. Of 910 evaluable Stage IV patients, 111 had brain metastases and 799 had non-brain metastases. Significant differences were observed between patients with brain metastases versus non-brain metastases for health status, QoL and activity-related impairments (TABLE). The percentage of work-related impairment was also numerically higher in patients with brain metastases. Figure 1



      Conclusion:
      Patients with A-NSCLC and secondary brain tumours had significantly worse health status and QoL, and experienced greater work- and activity-related impairments, compared with A-NSCLC patients with non-brain metastases. These findings may indicate a need for specific management/support programmes for patients with A-NSCLC and brain metastases.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.